Rodman & Renshaw Downgrades ABIOMED (ABMD) to Market Underperform, Price Target $6
Tweet Send to a Friend
Rodman & Renshaw downgraded ABIOMED (NASDAQ: ABMD) to a Market Underperform rating from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
